ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Conditions: Endometrial Cancer; Recurrent Endometrial Cancer; TP53 Interventions: Drug: Abemaciclib; Drug: Letrozole; Drug: Pembrolizumab Sponsors: Dana-Farber Cancer Institute; Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials